ArticleClinical & developmental immunology2013
Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain.
Article in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Experimental procedures for flow cytometry of wild-type mouse brain: a systematic review.Frontiers in immunology · 2023Pooled it
- The role of regulatory T cells in central nervous system diseases in dogs: fighting with a double-edged sword toward translational discoveries.American journal of translational research · 2025Review
- The immunosuppressive microenvironment and immunotherapy in human glioblastoma.Frontiers in immunology · 2022Review
- Review
- Regulatory T Cells as an Escape Mechanism to the Immune Response inFrontiers in cellular and infection microbiology · 2021Article
- Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.Frontiers in immunology · 2021Review
- IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.Oncoimmunology · 2020Article
- GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models.Scientific reports · 2020Article
- [The role of myeloid-derived suppressor cells in glioma microenvironment].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2019Review
- Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.Journal for immunotherapy of cancer · 2019Article
- CD4Journal of the American Heart Association · 2019Article
- High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with TCancer immunology, immunotherapy : CII · 2018Article
- Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.Frontiers in immunology · 2018Review
- Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.Oncotarget · 2017Article
- Engineering challenges for brain tumor immunotherapy.Advanced drug delivery reviews · 2017Review
- Anti-GITR therapy promotes immunity against malignant glioma in a murine model.Cancer immunology, immunotherapy : CII · 2016Article
- Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models.Neuro-oncology · 2016Article
- Brain Tumor Immunotherapy: What have We Learned so Far?Frontiers in oncology · 2015Review
- Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.Oncoimmunology · 2014Article
- Antibody-based immunotherapy for malignant glioma.Seminars in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recruitment and activation of regulatory T cells (Tregs) in the micro-environment of malignant brain tumors has detrimental effects on antitumoral immune responses. Hence, local elimination of Tregs within the tumor micro-environment represents a highly valuable tool from both a fundamental and clinical perspective. In the syngeneic experimental GL261 murine glioma model, Tregs were prophylactically eliminated through treatment with PC61, an anti-CD25 mAb. This resulted in specific elimination of CD4+CD25hiFoxp3+ Treg within brain-infiltrating lymphocytes and complete protection against subsequent orthotopic GL261 tumor challenge. Interestingly, PC61-treated mice also showed a pronounced infiltration of CD11b+ myeloid cells in the brain. Phenotypically, these cells could not be considered as Gr-1+ myeloid-derived suppressor cells (MDSC) but were identified as F4/80+ macrophages and granulocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.